ATLANTA – This fall, Americans over 50 will have the option to receive the first mRNA influenza vaccine ever developed, if their insurer agrees to pay for it. That decision rests with a federal advisory committee that has been legally unable to convene for four months, and whose June meeting, scheduled to run through Thursday, was canceled.
The Advisory Committee on Immunization Practices, known as ACIP, is the panel that determines how the Centers for Disease Control and Prevention recommends vaccines to the American public. When ACIP recommends a vaccine, private insurers are generally required to cover it under preventive care rules. When ACIP cannot meet, that path is blocked.
The committee has been in that position since March 16, when a federal judge in Massachusetts issued a stay that effectively stripped ACIP of its quorum. The ruling came in a lawsuit filed by the American Academy of Pediatrics and allied medical organizations, which argued that Health and Human Services Secretary Robert F. Kennedy Jr. had dismissed the prior committee’s expert members without following proper legal procedure and replaced them with individuals lacking traditional qualifications in vaccine science, according to NBC News.
Since then, the administration has tried three distinct approaches to restore the quorum. In April, it rewrote the ACIP charter to broaden membership criteria. In May, it rewrote the charter again. In late May, the White House issued an executive order. As of Thursday, the final day the June 24 to 26 committee session had been on the calendar since the beginning of the year, the quorum does not exist and the meeting remains canceled.
“The government has had and continues to have the power to restore a lawful ACIP and schedule a meeting at any time,” said Dr. Andrew Racine, president of the American Academy of Pediatrics, responding to Kennedy’s claim on social media that the court’s ruling is responsible for the committee’s paralysis. Kennedy filed a motion on June 12 asking the First Circuit Court of Appeals to expedite its review of the quorum dispute, arguing that without a functioning committee, vaccine recommendations for the fall respiratory season cannot be made.
The Moderna mRNA influenza vaccine, known as mFLUSIVA (mRNA-1010), is the most direct casualty of that stalemate. The FDA’s Vaccines and Related Biological Products Advisory Committee voted nine to zero on June 18 that the vaccine’s benefits outweigh its risks for adults aged 50 and older, according to meeting records published by the FDA. The agency’s formal approval decision is expected by August 5.
That timeline is months ahead of flu season. But the FDA decision grants only licensure. That function belongs to ACIP. Normally, once the FDA approves a new vaccine, ACIP convenes within weeks to vote on a recommendation specifying who should receive it and whether insurers must cover it. Without that recommendation, patients seeking mFLUSIVA could face out-of-pocket costs that several analysts have estimated at between $80 and $180 per dose.
The stakes extend beyond a single product. ACIP recommendations govern coverage for every vaccine in the adult immunization schedule. The paralysis of the committee means that no new vaccine approved by the FDA can move into standard covered care until the quorum is restored, a concern that the ongoing measles outbreak, which has now exceeded 2,100 confirmed cases across 41 states, has made considerably more urgent.
“This is not a narrow bureaucratic question about quorum rules,” said Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security who studies vaccine policy. “ACIP recommendations are how vaccines get from FDA approval into patients’ arms across the country, particularly for adults. If that mechanism is broken for any length of time, people don’t get vaccinated.”
The timing is further complicated by a new ACIP charter that the administration disclosed last week. The document substantially refocuses the committee’s responsibilities: it includes a mandate to review “alternatives to vaccines” for disease prevention and to advise on the “cumulative effects” of giving all recommended childhood vaccines simultaneously, as well as the chemical components of individual vaccines. Critics argue the new charter is designed to orient the committee around Kennedy’s long-held skepticism of standard vaccine practice rather than to restore it to functioning order. Kennedy has argued the changes represent a return to scientific rigor, contending in past interviews that the original ACIP had become too close to pharmaceutical industry interests.
Non-voting membership in the reconstituted ACIP has been extended to several medical organizations that have publicly expressed skepticism of vaccines, including the Independent Medical Alliance, Physicians for Informed Consent, and the Association of American Physicians and Surgeons.
ACIP has historically met three times per year, in February, June, and October, to review newly approved vaccines, update childhood immunization schedules, and issue guidance for seasonal vaccines. The February 2026 meeting was also canceled, after the administration failed to post a public agenda within the legally required timeframe. A March meeting was eventually convened, but the American Academy of Pediatrics and most major medical associations withdrew their liaison representatives to protest the new committee’s composition.
The ACIP paralysis arrives alongside other disruptions in federal vaccine policy. The Defense Department reversed a flu vaccine opt-out policy this week after 275 recruits fell ill at Lackland Air Force Base in San Antonio in what doctors described as a preventable outbreak. The Pentagon had implemented the opt-out directive under Defense Secretary Pete Hegseth in a policy change that public health officials had warned would create exactly this kind of concentrated exposure risk.
What none of the parties to the ongoing litigation have publicly addressed is what happens to Moderna’s mRNA flu vaccine if the quorum dispute is not resolved before August 5. The FDA decision is expected on that date. The next ACIP meeting, even if it could be legally convened, would typically occur in October. That gap could mean a licensed, available vaccine, recommended unanimously by an independent panel, sitting on pharmacy shelves without insurance coverage for the first months of flu season. The CDC has not responded publicly to questions about contingency plans if that scenario materializes.
Researchers studying H5N1 avian influenza, including those who recently identified H5N1’s cow tissue binding, have also raised concerns about ACIP’s inability to review and issue timely guidance on emerging infectious disease threats. The committee is the mechanism through which the CDC makes the transition from scientific finding to actionable public health recommendation, and as of Thursday, that mechanism is still offline.
